Sequent Scientific Limited
Indranil Chowdhury is a seasoned professional with extensive experience in sales and business development within the pharmaceutical industry. Currently serving as Associate Vice President of Global Business Development at Sequent Scientific Limited since May 2021, Indranil leads API sales and business development initiatives. Prior roles include Director of Sales and Business Development at Kyowa Hakko USA, and Vice President of Sales, Business Development & Logistics at Kyowa Hakko Bio India Private Limited, contributing to the growth of their Indian subcontinent operations. Indranil's earlier experience includes roles at Goldshield, Elder Pharma, NEPC Pharma, and Max Pharma, where responsibilities encompassed market evaluation, business development, and team management. Indranil holds multiple degrees in marketing and chemistry from prestigious institutions, including SVKM's Narsee Monjee Institute of Management Studies and R. D. National College.
This person is not in any offices
Sequent Scientific Limited
4 followers
SeQuent Scientific Limited is India’s largest and amongst the ‘Top 20’ global animal health companies, backed by global investment firm ‘The Carlyle Group’ as the promoter. The company has 8 manufacturing facilities across Europe, Turkey, Brazil & India with the Vizag site being India’s only USFDA approved dedicated veterinary API facility. SeQuent offers a comprehensive portfolio of finished drug formulations, active pharmaceutical ingredients along with analytical services, which address the needs of the global animal health sector.